Nikhil C. Munshi

Signatures of mutational processes in human cancer

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell Cancer

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

Somatic<i>SF3B1</i>Mutation in Myelodysplasia with Ring Sideroblasts

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma